Skip to content

Study · Not a test of the peptide alone · 2021

8 results

Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis.

Ryan PM, Seltzer S, Hayward NE, Rodriguez DA, Sless RT, Hawkes CP

The Journal of pediatrics11 May 2021Cited by 82 (Europe PMC)

PMID33984333 (opens in a new tab)DOI10.1016/j.jpeds.2021.05.009 (opens in a new tab)PepBankPUB-33984333
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

ObjectivesTo determine the weight, body mass index (BMI), cardiometabolic, and gastrointestinal effects of glucagon-like peptide-1 (GLP-1) receptor agonists in children with obesity.Study designWeb of Science, PubMed/MEDLINE, and Scopus databases from 01/01/1994-01/01/2021 for randomized control trials examining the weight, BMI, cardiometabolic, or gastrointestinal effects of GLP-1 receptor agonists in children and adolescents with obesity. Data were extracted by 2 independent surveyors and a random effects model was applied to meta-analyze generic inverse variance outcomes. Primary outcomes were related to weight and cardiometabolic profile, and secondary outcomes of interest were gastrointestinal-related treatment-emergent adverse events.ResultsNine studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved liraglutide. GLP-1 receptor agonists use caused a modest reduction in body weight (mean difference [MD] -1.50 [-2.50,-0.50] kg, I2 64%), BMI (MD -1.24 [-1.71,-0.77] kg/m2, I2 0%), and BMI z score (MD -0.14 [-0.23,-0.06], I2 43%). Glycemic control was improved in children with proven insulin resistance (glycated hemoglobin A1c MD -1.05 [-1.93,-0.18] %, I2 76%). Although no lipid profile improvements were noted, a modest decrease in systolic blood pressure was detected (MD -2.30 [-4.11,-0.49] mm Hg; I2 0%). Finally, analysis of gastrointestinal-related treatment-emergent adverse events revealed an increased risk of nausea (risk ratio 2.11 [1.44, 3.09]; I2 0%), without significant increases in other gastrointestinal symptoms.ConclusionsThis meta-analysis indicates that GLP-1 receptor agonists are safe and effective in modestly reducing weight, BMI, glycated hemoglobin A1c, and systolic blood pressure in children and adolescents with obesity in a clinical setting, albeit with increased rates of nausea.Prospero idCRD42020195869.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In children and adolescents with obesity, pooled GLP-1 receptor agonists (exenatide and liraglutide) modestly reduced body weight (MD -1.50 kg).

    In plain wordsIn children and adolescents with obesity, the GLP-1 drug class (exenatide and liraglutide) modestly reduced body weight.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Comparator
    Control
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    MD body weight
    −1.5 kg
    pooled GLP-1 RAs

    Source sentences

    Summary
    GLP-1 receptor agonists use caused a modest reduction in body weight (mean difference [MD] -1.50 [-2.50,-0.50] kg, I2 64%)
    1 context sentence
    Summary · context
    Nine studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In children and adolescents with obesity, pooled GLP-1 receptor agonists (exenatide and liraglutide) reduced BMI (MD -1.24 kg/m2).

    In plain wordsIn children and adolescents with obesity, the GLP-1 drug class (exenatide and liraglutide) lowered BMI.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI
    Study

    n: not reported in source

    Comparator
    Control
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    MD BMI
    −1.24 kg/m2
    pooled GLP-1 RAs

    Source sentences

    Summary
    BMI (MD -1.24 [-1.71,-0.77] kg/m2, I2 0%)
    1 context sentence
    Summary · context
    Nine studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In children and adolescents with obesity, pooled GLP-1 receptor agonists (exenatide and liraglutide) reduced BMI z score (MD -0.14).

    In plain wordsIn children and adolescents with obesity, the GLP-1 drug class (exenatide and liraglutide) lowered BMI z score.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI z score
    Study

    n: not reported in source

    Comparator
    Control
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    MD BMI z score
    −0.14
    pooled GLP-1 RAs

    Source sentences

    Summary
    BMI z score (MD -0.14 [-0.23,-0.06], I2 43%)
    1 context sentence
    Summary · context
    Nine studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In children and adolescents with obesity, pooled GLP-1 receptor agonists (exenatide and liraglutide) increased the risk of nausea (risk ratio 2.11).

    In plain wordsIn children and adolescents with obesity, the GLP-1 drug class (exenatide and liraglutide) was linked to more nausea.

    Peptide
    Liraglutide
    Outcome
    IncreaseNausea
    Study

    n: not reported in source

    Comparator
    Control
    Analysis
    Secondary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Measurements

    Risk ratio nausea
    2.11
    pooled GLP-1 RAs

    Source sentences

    Summary
    analysis of gastrointestinal-related treatment-emergent adverse events revealed an increased risk of nausea (risk ratio 2.11 [1.44, 3.09]; I2 0%)
    1 context sentence
    Summary · context
    Nine studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In children and adolescents with obesity, pooled GLP-1 receptor agonists (exenatide and liraglutide) did not significantly increase other gastrointestinal symptoms.

    In plain wordsIn children and adolescents with obesity, the GLP-1 drug class (exenatide and liraglutide) did not clearly raise other stomach and gut symptoms.

    Peptide
    Liraglutide
    Outcome
    No significant changeOther gastrointestinal symptoms
    Study

    n: not reported in source

    Comparator
    Control
    Analysis
    Secondary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    without significant increases in other gastrointestinal symptoms.
    1 context sentence
    Summary · context
    Nine studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In children with obesity and proven insulin resistance, pooled GLP-1 receptor agonists (exenatide and liraglutide) improved glycemic control (HbA1c MD -1.05 %).

    In plain wordsIn children with obesity and insulin resistance, the GLP-1 drug class (exenatide and liraglutide) improved long-term blood sugar.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c in children with proven insulin resistance
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    MD HbA1c
    −1.05%
    children with insulin resistance

    Source sentences

    Summary
    Glycemic control was improved in children with proven insulin resistance (glycated hemoglobin A1c MD -1.05 [-1.93,-0.18] %, I2 76%).
    1 context sentence
    Summary · context
    Nine studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In children and adolescents with obesity, pooled GLP-1 receptor agonists (exenatide and liraglutide) showed no lipid profile improvements.

    In plain wordsIn children and adolescents with obesity, the GLP-1 drug class (exenatide and liraglutide) did not improve blood fats.

    Peptide
    Liraglutide
    Outcome
    No significant changeLipid profile
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Although no lipid profile improvements were noted, a modest decrease in systolic blood pressure was detected (MD -2.30 [-4.11,-0.49] mm Hg; I2 0%).
    1 context sentence
    Summary · context
    Nine studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In children and adolescents with obesity, pooled GLP-1 receptor agonists (exenatide and liraglutide) modestly decreased systolic blood pressure (MD -2.30 mm Hg).

    In plain wordsIn children and adolescents with obesity, the GLP-1 drug class (exenatide and liraglutide) modestly lowered systolic blood pressure.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    MD systolic blood pressure
    −2.3 mm Hg
    pooled GLP-1 RAs

    Source sentences

    Summary
    a modest decrease in systolic blood pressure was detected (MD -2.30 [-4.11,-0.49] mm Hg; I2 0%)
    1 context sentence
    Summary · context
    Nine studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.